uploads///seedling _

Oppenheimer Initiates Coverage on Tilray, Stock Falls


Jun. 5 2019, Published 3:53 p.m. ET

New coverage

Oppenheimer has initiated coverage on Tilray (TLRY) with a “perform” rating. Usually, such a rating is equivalent to a “neutral” or a “hold” rating. Today, Tilray stock has continued to slide, falling almost 2.5%.

Article continues below advertisement

What’s the consensus?

The 12 analysts covering Tilray stock in June have a consensus “hold” rating on Tilray. Tilray also has a consensus price target of $94 in the month. Based on its current price of ~$35.6, Tilray has a potential upside of ~159%.

The market is mixed

The overall cannabis market has been broadly mixed today, with Canopy Growth (WEED), Aphria (APHA), and Aurora Cannabis (ACB) down ~1%, 1.5%, and 2%, respectively.

On the other hand, Cronos Group (CRON) was up 8.5% after it received an upgrade from Bank of America Merrill Lynch. The weakness in the cannabis sector is enduring despite BAML’s optimism. Read BAML Projects CBD Will Become $11.5 Billion Market by 2032 to learn more.

Investors are exercising caution on the cannabis sector as market volatility remains high. Given the choppy markets, holding on to cannabis stocks is challenging, especially as the decline in the sector affects cannabis players’ returns. To learn more about our take on the matter, read Should You Hold On to Your Cannabis Stocks?


More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.